Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study

References

• Kakizaki H, Kita M, Watanabe M, et al. Pathophysiological and therapeutic considerations for non-neurogenic lower urinary tract dysfunction in children. Low Urin Tract Symptoms. 2016;8:75–85.
   Web of Science ®Google Scholar
• Fabuel Alcañiz JJ, Martínez Arcos L, Jimenez Cidre M, et al. [Intravesical botulinum toxin under local anestesia as ambulatory procedure]. Arch Esp Urol. 2017;70: 635–644. [Article in Spanish].
   Web of Science ®Google Scholar
• Franco I. Functional bladder problems in children: pathophysiology, diagnosis, and treatment. Pediatr Clin North Am. 2012;59:783–817.
   Web of Science ®Google Scholar
• Pogonchenkova IV, Khan MA, Korchazhkina NB, et al. [The application of the physical factors for the medical rehabilitation of the children presenting with neurogenic dysfunction of the bladder]. Vopr Kurortol Fizioter Lech Fiz Kult. 2017;94: 53–58. [Article in Russian].
   Google Scholar
• Tugtepe H, Thomas DT, Ergun R, et al. Comparison of biofeedback therapy in children with treatment-refractory dysfunctional voiding and overactive bladder. Urology. 2015;85:900–904.
   Web of Science ®Google Scholar
• Malm-Buatsi E, Nepple KG, Boyt MA, et al. Efficacy of transcutaneous electrical nerve stimulation in children with overactive bladder refractory to pharmacotherapy. Urology. 2007;70:980–983.
   Web of Science ®Google Scholar
• Jr BU, Carvalho MT, Veiga ML, et al. Urodynamic outcome of parasacral transcutaneous electrical neural stimulation for overactive bladder in children. Int Braz J Urol. 2015;41:739–743.
   Web of Science ®Google Scholar
• Tincello DG, Rashid T, Revicky V. Emerging treatments for overactive bladder: clinical potential of botulinum toxins. Res Rep Urol. 2014;6:51–57.
   Google Scholar
• Sanford M. OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury. Drugs. 2014;74:1659–1672.
   Web of Science ®Google Scholar
• Kaviani A, Khavari R. Disease-specific outcomes of botulinum toxin injections for neurogenic detrusor overactivity. Urol Clin North Am. 2017;44:463–474.
   Web of Science ®Google Scholar
• Harris S, Rizzolo D. Botulinum toxin as a treatment for refractory overactive bladder. Jaapa. 2016;29:1–4.
   PubMedGoogle Scholar
• Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology. 2006;68:318–323.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): A single-item global measure for patients with overactive bladder. Eur Urol. 2006;49:1079–1086.
   PubMed Web of Science ®Google Scholar
• Neveus T, von Gontard A, Hoebeke P et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children’s Continence Society. J Urol 2006; 176:314–324.
   Google Scholar
• McDowell DT, Noone D, Tareen F, et al. Urinary incontinence in children: botulinum toxin is a safe and effective treatment option. Pediatr Surg Int. 2012;28:315–320.
   PubMed Web of Science ®Google Scholar
• Quintiliano F, Veiga ML, Moraes M, et al. Transcutaneous parasacral electrical stimulation vs oxybutynin for the treatment of overactive bladder in children: a randomized clinical trial. J Urol. 2015;193(Suppl.):1749–1753.
   Google Scholar
• Gleason JM, Daniels C, Williams K, et al. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration. J Pediatr Urol. 2014;10:753–757.
   PubMed Web of Science ®Google Scholar
• Khan MK, Van der Brink BA, De Foor WR, et al. Botulinum toxin injection in the pediatric population with medically refractory neuropathic bladder. J Pediatr Urol. 2016;12:104.e1–6.
   Web of Science ®Google Scholar
• Ladi-Seyedian SS, Sharifi-Rad L, Kajbafzadeh AM. Intravesical electromotive botulinum toxin type “A” administration for management of urinary incontinence secondary to neuropathic detrusor overactivity in children: long-term follow-up. Urology. 2018;114:167–174.
   Web of Science ®Google Scholar
• Lane GI, Gor RA, Katorski J, et al. Clinical outcomes of non-surgical management of detrusor leak point pressures above 40 cm water in adults with congenital neurogenic bladder. Neurourol Urodyn. 2018. Epub ahead of print. DOI:10.1002/nau.23535
   Web of Science ®Google Scholar
• Lahdes-Vasama TT, Anttila A, Wahl E, et al. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study. Scand J Urol Nephrol. 2011;45:397–400.
   PubMed Web of Science ®Google Scholar
• Santos-Silva A, Da Silva CM, Cruz F. Botulinum toxin treatment for bladder dysfunction. Int J Urol. 2013;20:956–962.
   Web of Science ®Google Scholar
• Léon P, Jolly C, Binet A, et al. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children. J Pediatr Surg. 2014;49:1424–1428.
   PubMed Web of Science ®Google Scholar
• ‘t Hoen LA, van den Hoek J, Wolffenbuttel KP, van der Toorn F, Scheepe JR. Breaking the vicious circle: Onabotulinum toxin A in children with therapy-refractory dysfunctional voiding. J Pediatr Urol. 2015. 11119.e1–6.
   Web of Science ®Google Scholar
• Bottet F, Peyronnet B, Boissier R, et al. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed. Neurourol Urodyn. 2018;37:291–297.
   Web of Science ®Google Scholar